CoChat

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Open access

The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.

Abstract

Gene therapy has the potential to maintain therapeutic blood clotting factor IX (FIX) levels in patients with hemophilia B by delivering a functional human F9 gene into liver cells. This phase 1/2, open-label dose-escalation study investigated BAX 335 (AskBio009, AAV8.sc-TTR-FIXR338Lopt), an adeno-associated virus serotype 8 (AAV8)–based FIX Padua gene therapy, in patients with hemophilia B. This report focuses on 12-month interim analyses of safety, pharmacokinetic variables, effects on FIX activity, and immune responses for dosed participants. Eight adult male participants (aged 20-69 years; range FIX activity, 0.5% to 2.0%) received 1 of 3 BAX 335 IV doses: 2.0 × 1011; 1.0 × 1012; or 3.0 × 1012 vector genomes/kg. Three (37.5%) participants had 4 serious adverse events, all considered unrelated to BAX 335. No serious adverse event led to death. No clinical thrombosis, inhibitors, or other FIX Padua–directed immunity was reported. FIX expression was measurable in 7 of 8 participants; peak FIX activity displayed dose dependence (32.0% to 58.5% in cohort 3). One participant achieved sustained therapeutic FIX activity of ∼20%, without bleeding or replacement therapy, for 4 years; in others, FIX activity was not sustained beyond 5 to 11 weeks. In contrast to some previous studies, corticosteroid treatment did not stabilize FIX activity loss. We hypothesize that the loss of transgene expression could have been caused by stimulation of innate immune responses, including CpG oligodeoxynucleotides introduced into the BAX 335 coding sequence by codon optimization. This trial was registered at www.clinicaltrials.gov as #NCT01687608.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019004625

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 199

Metadata

Authors
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., Reipert, B. M., Rottensteiner, H., Scheiflinger, F., Chapin, J. C., Ewenstein, B., & Monahan, P. E.
Affiliations
  • University of Washington (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • The University of Texas Health Science Center at Houston (US)
  • University of Southern California (US)
  • Hemophilia and Thrombosis Treatment Center, University of California, San Diego, CA;
  • AskBio (United States) (US)
  • University of North Carolina at Chapel Hill (US)
  • Baxalta Innovations GmbH, a member of the Takeda group of companies, Vienna, Austria; and
  • Takeda (Austria) (AT)
  • Baxalta US Inc., a member of the Takeda group of companies, Cambridge, MA
Venue
Blood
Published
2021-02-11
Volume
137
Issue
6
Pages
763-774
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3093323554
Cited by
189
References
50
Citations by year
2026: 24 · 2025: 29 · 2024: 44 · 2023: 33 · 2022: 38 · 2021: 21
FWCI
14.53
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
National Heart, Lung, and Blood Institute (RC3HL103396)
Topics
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
hemophilia B, gene therapy, AAV8, factor IX, F9 gene, CpG oligodeoxynucleotides, innate immune response, codon optimization, corticosteroid therapy, dose escalation, factor IX activity, liver-directed gene delivery
MeSH terms
Pathogen-Associated Molecular Pattern Molecules, Gain of Function Mutation, Adolescent, Adult, Aged, Hemophilia B, Factor IX, Gene Expression Regulation, Humans, Immunity, Innate, Male, Middle Aged, Prospective Studies, Recombinant Fusion Proteins, Rhabdomyolysis, Genetic Therapy, CpG Islands, Transgenes, Toll-Like Receptor 9, Young Adult, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. https://app.cochat.ai/papers/10.1182/blood.2019004625
The paper
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., Reipert, B. M., Rottensteiner, H., Scheiflinger, F., Chapin, J. C., Ewenstein, B., & Monahan, P. E. (2021). BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. https://doi.org/10.1182/blood.2019004625

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.